BTNL2 Antibody

Code CSB-PA883443ESR2HU
Size US$166
Order now
Image
  • Western blot
    All lanes: BTNL2antibody at 4.12μg/ml
    Lane 1: Mouse small intestine tissue
    Lane 2: K562 whole cell lysate
    Lane 3: HepG2 whole cell lysate
    Lane 4: HL60 whole cell lysate
    Secondary
    Goat polyclonal to rabbit IgG at 1/10000 dilution
    Predicted band size: 51, 44, 31, 28, 20, 29 kDa
    Observed band size: 51 kDa

  • Immunohistochemistry of paraffin-embedded human pancreatic tissue using CSB-PA883443ESR2HU at dilution of 1:100

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) BTNL2 Polyclonal antibody
Uniprot No.
Target Names
BTNL2
Alternative Names
BTNL2Butyrophilin-like protein 2 antibody; BTL-II antibody
Raised in
Rabbit
Species Reactivity
Human, Mouse
Immunogen
Recombinant Human Butyrophilin-like protein 2 protein (246-455AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Polyclonal
Isotype
IgG
Purification Method
Antigen Affinity Purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Form
Liquid
Tested Applications
ELISA, WB, IHC
Recommended Dilution
Application Recommended Dilution
WB 1:1000-1:5000
IHC 1:20-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

CUSABIO uses the peptide mapping within amino acids 246-455 of the recombinant human BTNL2 to immunize rabbits to yield the anti-BTNL2 antibody. It is a polyclonal antibody and occurs as an unconjugated IgG. And it underwent antigen affinity purified. This BTNL2 antibody can detect with human and mouse BTNL2 protein, an MHC class II gene-linked butyrophilin-like molecule, with the human autoimmune diseases sarcoidosis and myositis. And it has been verified to recognize the BTNL2 protein in ELISA, WB, and IHC applications.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Negative regulator of T-cell proliferation.
Gene References into Functions
  1. Host-genotype analysis revealed an association of the rs2076530 (BTNL2) risk allele with a decrease in bacterial burden in sarcoidosis. PMID: 29242257
  2. HLA-DPB1*05:01 gene was associated with the geographical region of PV and the BTNL2 gene was significantly associated with family history and age of onset of PV. In conclusion, the HLA-DPB1*05:01 and BTNL2 genes might be responsible for the complicacy of clinical features. PMID: 28581127
  3. The sarcoidosis risk variant BTNL2 c.1078G.A (rs2076530) was associated with disease in all OFG cases (P (1/4) 0.013; OR (1/4) 1.33; 95% CI, 1.06-1.67) and had a similar OR (1.56) and the same direction of effect as seen in sarcoidosis. However, no association was seen for the subphenotypes of OFG only or OFG+CD. PMID: 27306066
  4. Despite a significant difference in BTNL2 polymorphism between sarcoid patients and controls, there was no such difference between familial and sporadic sarcoidosis cases and no correlation between BTNL2 polymorphism and disease severity or outcome. Thus, BTNL2 difference cannot be considered as a key marker for disease classification or patient management. PMID: 27914482
  5. Two new signals were observed at genome-wide significance (P < 5 x 10-8), namely, rs7216064 (17q24.3, BPTF), for overall lung adenocarcinoma risk, and rs3817963 (6p21.3, BTNL2) which is specific to cases with EGFR mutations. In further sub-analyses by EGFR status, rs9387478 (ROS1/DCBLD1) and rs2179920 (HLA-DPB1) showed stronger estimated associations in EGFR-positive compared to EGFR-negative cases PMID: 28025329
  6. BTNL2 variant is associated with psoriasis. PMID: 27213287
  7. Butyrophilin-like 2, expressed at various levels by UM cells and macrophages, might interfere with the immune control of the tumor. Butyrophilin-like 2 variants showed highly variable frequencies among ethnically related cohorts. There was no enrichment of BTNL2 variants in patients with UM compared with control patients. PMID: 27532663
  8. BTNL2 G16071A gene polymorphism may as a likelihood factor contributed to granulomatous disease susceptibility, especially increasing the sarcoidosis susceptibility. In addition, the polymorphism may be greatly associated with likelihood of granulomatous diseases among Caucasians. PMID: 27472712
  9. BTNL2 may have an inhibitory effect on FOXP3(+) T cell proliferation, especially in patients homozygous for the risk alleles. PMID: 26679868
  10. genetic mutations within or around BTNL2 (rs3763313, rs9268494, rs9268492 and rs9268402) could alter susceptibility to grade IV of dilated cardiomyopathy in a Chinese population PMID: 26617759
  11. Results confirm the association of BTNL2 rs2076530SNP with the susceptibility to develop sarcoidosis, but not with an increased risk of cancer in these patients. PMID: 25078641
  12. BTNL2 rs2076530 polymorphism contributes to the risk of sarcoidosis PMID: 25849037
  13. Two independent loci near BTNL2 (rs9461741) and HLA-B (rs2922994) in the HLA region significantly associated with Marginal Zone B-Cell Lymphoma risk. PMID: 25569183
  14. The association of the rare variant p.G454C in BTNL2 reached genome-wide significance, and was independent of the known common risk variants for IBD in the HLA region in both a conditional and haplotype analysis PMID: 25671699
  15. These findings suggest that polymorphisms in the BTNL2 gene might play a vital role in determining the outcome of the immune response to hepatitis B vaccination. PMID: 24664813
  16. No variation except in the 329-bp region containing the BTNL2 rs2076530 polymorphism was found in Turkish patients with sarcoidosis. PMID: 25551927
  17. Rare BTNL2 variants play a role in susceptibility to both familial and sporadic prostate cancer. Results implicate BTNL2 as a novel prostate cancer susceptibility gene. PMID: 23833122
  18. the BTNL2 splice site polymorphism (A variant of rs2076530) shows association with an increased risk for persistent sarcoidosis PMID: 23904553
  19. sequenced single-nucleotide variants in an association study of 432 cases and 432 controls showed that 12 non-synonymous single-nucleotide polymorphisms (SNPs) in BTNL2 were significantly associated with RA PMID: 23364395
  20. Results show that single nucleotide polymorphism associated with BTNL2 gene is a risk factor for predisposition pulmonary sarcoidosis PMID: 23017494
  21. Upon stratification analysis in search for a synergistic effect in sarcoidosis given the extensive linkage disequilibrium between BTNL2 rs2076530_A and HLA-DRB1*08:03; the risk-bearing allele of these two loci interact negatively. PMID: 22991420
  22. We unravel the role of unexplored immunologically important genes, BAT1 and BTNL2, and the haplotypes of the significantly associated SNPs therein, to understand susceptibility to the disease, leprosy and its differential severity. PMID: 22071774
  23. The rs10947262 and rs7775228 variants are not associated with risk of knee osteoarthritis in European descent populations. PMID: 21853121
  24. The BTNL2 A allele variant occurs with a high frequency in Danish patients with sarcoidosis PMID: 21410903
  25. The presence of a BTNL2G16071A variant allele almost doubles the risk of progressing to persistent pulmonary sarcoidosis in addition to increasing the risk of developing sarcoidosis. PMID: 21256912
  26. preliminary data suggest that BTNL2 polymorphism may be associated with susceptibility to Kawasaki disease and coronary artery lesions in Taiwanese children PMID: 19882345
  27. This genetic study reveals a significant association between the rs3763313, rs9268494, rs9268492 SNPs in the BTNL2 gene and tuberculosis. PMID: 20176143
  28. the absence of a membrane anchored BTNL2 protein may increase genetic susceptibility to sarcoidosis and familial occurrence of the disease. PMID: 20560297
  29. Sarcoidosis is associated with a truncating splice site mutation in BTNL2 PMID: 15735647
  30. BNTL2 associates with sarcoidosis in both White Americans and African-Americans, with risk effects in Whites independent of HLA-DRB1 associations, and negative interactions between BRNL2 and HLA classII in African-Americans. PMID: 16080124
  31. Association of the truncating splice site mutation in BTNL2 with multiple sclerosis is secondary to HLA-DRB1*15. PMID: 16321988
  32. resiults show that BTNL2 rs2076530 polymorphism is associated with type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus because of its strong linkage disequalibrium with predisposing HLA DQB1-DRB1 haplotypes in Caucasian populations PMID: 16690410
  33. RAGE and its ligands with sarcoidosis and suggest that an intrinsic genetic factor could be in part involved in its expression. In Italian patients, the -374 T/A polymorphism seems to be significantly associated with this disease. PMID: 17170388
  34. Structural analysis of BTNL2 shows a molecule with an extracellular region containing two sets of two Ig domains, a transmembrane region, and a previously unreported cytoplasmic tail PMID: 17237401
  35. Coding regions of BTNL2 were sequenced to detect known and novel polymorphisms and genotyped 18 SNPs in 432 pulmonary tuberculosis cases and 482 controls. PMID: 17347014
  36. a major effect of the BTNL2 rs2076530 (G --> A) SNP in Crohn's disease and tuberculosis was excluded; there was an association with susceptibility to leprosy (P=0.04), however, this is most likely due to linkage disequilibrium with HLA-DR PMID: 17493147
  37. Does not contribute to susceptibility to Crohn's disease in Japan but is associated with Japanese ulcerative colitis because of strong linkage disequilibrium with HLA-DRB1*1502. PMID: 17610417
  38. Some haplotypes are associated with non-Lofgren sarcoidosis. PMID: 17661910
  39. Both DRB1*13 and BTNL2 rs3117099TT homozygosity are associated with chronic beryllium disease [CBD] in *Glu69-negative subjects, while DPB1*Glu69 is associated with CBD and Be sensitivity compared with Be exposed PMID: 17927685
  40. BTNL2 gene might be one of the candidate genes that is responsible for the pathogenesis of Dermatophagoides farinae (Der f)-specific IgE responsiveness. PMID: 19050377
  41. Genome-wide significant evidence for association was found in a region spanning BTNL2 to HLA-DQB1 on chromosome 6p21 for ulcerative colitis. PMID: 19122664
  42. The CNV_ID 507 was tested for association in a cohort of 89 sarcoidosis patients and 89 matched controls, but our results indicated that CNV_ID 507 does not affect the genomic structure of BTLN2 as previously described PMID: 19140834
  43. Single-nucleotide polymorphism in the BTNL2 gene is associated with ulcerative colitis. PMID: 19659809

Show More

Hide All

Involvement in disease
Sarcoidosis 2 (SS2)
Subcellular Location
Membrane; Single-pass type II membrane protein. Note=Isoform 2 is present in the nuclear, vesicle and plasma membranes, isoform 3 is found in cytoplasmic vesicle structures and is not membrane bound.
Protein Families
Immunoglobulin superfamily, BTN/MOG family
Tissue Specificity
Expressed in brain, heart, kidney, liver, pancreas, ovary, leukocyte, small intestine, testis and thymus.
Database Links

HGNC: 1142

OMIM: 606000

KEGG: hsa:56244

STRING: 9606.ENSP00000419512

UniGene: Hs.534471

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*